EpiVax Launches AI-Enhanced Models for Immunogenicity Prediction
PROVIDENCE, R.I., Sept. 3, 2026 /PRNewswire/ -- EpiVax, Inc. is pleased to announce the release of AI-enabled enhancements to ISPRI™, its proprietary in silico platform for assessing the immunogenicity risk of biotherapeutics. The release introduces...